Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

5 ways machine learning is transforming portfolio management
Pardeep Bassi from WTW looks at how machine learning and AI are giving insurers a measurable edge in portfolio management - and are quickly becoming a
The future for professional trustees in a changing market
Our recent conversations with professional trustees reveal mixed views about a future shaped by regulatory change and the direction of the DB pensions
6 key ingredients to an effective cancer prevention strategy
Globally, cancer is one of the most common conditions being faced, which in turn is leading to rising costs according to our Global Medical Trends 202

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.